Neurogene Inc. (NGNE): Depreciation & Amortization
$3.04M
Year ended 2025-12-31
$3.20M
Trailing 12 months to 2026-06-30
-1.6%
3-year compound annual growth
+31.1%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.04M | -4.8% | 2026-03-24, From 2025-01-01 |
| 2024-12-31 | $3.19M | -2.1% | 2026-03-24, From 2024-01-01 |
| 2023-12-31 | $3.26M | +2.1% | 2025-03-24, From 2023-01-01 |
| 2022-12-31 | $3.20M | +144.7% | 2024-03-18, From 2022-01-01 |
| 2021-12-31 | $1.31M | +66.4% | 2023-03-20, From 2021-01-01 |
| 2020-12-31 | $785.0K | +130.9% | 2022-03-01, From 2020-01-01 |
| 2019-12-31 | $340.0K | +17.6% | 2021-03-25, From 2019-01-01 |
| 2018-12-31 | $289.0K | -19.7% | 2020-03-12, From 2018-01-01 |
| 2017-12-31 | $360.0K | n/a | 2020-03-12, From 2017-01-01 |
| No annual figure between 2014-12-31 and 2017-12-31. | |||
| 2014-12-31 | $135.9K | +128.2% | 2015-03-16, From 2014-01-01 |
| 2013-12-31 | $59.6K | -54.5% | 2015-03-16, From 2013-01-01 |
| 2012-12-31 | $130.8K | n/a | 2015-03-16, From 2012-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Neurogene Inc. (NGNE) | 2025-12-31 | $3.04M | -4.8% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $4.01B | -58.2% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $384.0K | -24.6% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $2.00B | +13.0% |
| Pfizer Inc (PFE) | 2025-12-31 | $6.59B | -6.0% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $7.50B | +2.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $13.84M | -2.6% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $146.0K | -16.1% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $2.31M | -7.1% |
Compare NGNE, BMY, TXMD, LLY side by side · Screen every company in Pharmaceutical Preparations ↗